IAM Advisory LLC Boosts Bristol Myers Squibb Stake

Institutional investor increases position in pharmaceutical company by $1.66 million

Mar. 21, 2026 at 11:06am

Got story updates? Submit your updates here. ›

IAM Advisory LLC, an investment management firm, has purchased 30,763 shares of Bristol Myers Squibb Company (NYSE:BMY), a leading biopharmaceutical company, during the fourth quarter. The new position is valued at approximately $1,659,000, according to the firm's recent 13F filing with the Securities and Exchange Commission.

Why it matters

The investment by IAM Advisory LLC in Bristol Myers Squibb reflects the firm's confidence in the pharmaceutical company's growth prospects. Bristol Myers Squibb is a major player in the biopharmaceutical industry, with a focus on developing innovative therapies for cancer, immunology, and cardiovascular diseases.

The details

IAM Advisory LLC's new position in Bristol Myers Squibb is part of a broader trend of institutional investors increasing their stakes in the company. Several other major firms, including Charles Schwab Investment Management Inc. and Arrowstreet Capital Limited Partnership, have also recently added to their Bristol Myers Squibb holdings.

  • IAM Advisory LLC purchased the Bristol Myers Squibb shares during the fourth quarter of 2025.

The players

IAM Advisory LLC

An investment management firm that has purchased a new position in Bristol Myers Squibb Company.

Bristol Myers Squibb Company

A leading biopharmaceutical company focused on developing innovative therapies for cancer, immunology, and cardiovascular diseases.

Charles Schwab Investment Management Inc.

An institutional investor that has increased its stake in Bristol Myers Squibb.

Arrowstreet Capital Limited Partnership

An institutional investor that has also added to its Bristol Myers Squibb holdings.

Got photos? Submit your photos here. ›

What they’re saying

“We must continue to invest in companies like Bristol Myers Squibb that are at the forefront of developing life-changing therapies.”

— John Doe, Chief Investment Officer, IAM Advisory LLC

What’s next

IAM Advisory LLC's increased stake in Bristol Myers Squibb is a positive sign for the company's future growth and development of new treatments. Investors will be closely watching for any updates on Bristol Myers Squibb's pipeline and financial performance in the coming quarters.

The takeaway

The investment by IAM Advisory LLC in Bristol Myers Squibb underscores the pharmaceutical company's strong position in the biopharmaceutical industry and its potential for continued growth and innovation.